The Best Marijuana Stock to Own for the Next 50 Years

Hexo Corp. (TSX:HEXO)(NYSE:HEXO) is building a cannabis business ready to grow for decades to come.

| More on:
edit Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

The past two years have been a roller coaster ride for marijuana investors. In 2018, cannabis stocks were regularly doubling in price. In 2019, they were regularly halving in the price.

Despite the whirlwind, the pot industry still has a strong decade of growth ahead of it.

Cowen Inc, the leading voice on cannabis stocks, thinks that the U.S. will generate $85 billion in sales by 2030. That’s up from a previous estimate of $80 billion. The firm believes federal legalization in the U.S. should occur by the end of the decade.

In Canada, Cowen believes the market size will eventually approach $5.2 billion. Its previous forecast was $4.8 billion, so Canadian prospects are also on the rise. Notably, the “Cannabis 2.0” phenomenon could add an additional $2.3 billion in near-term sales.

The cannabis bear market of 2019 has created some clear buying opportunities; just be sure to pinpoint stocks that can benefit from U.S. legalization and the rise of Cannabis 2.0 in Canada.

Don’t miss this opportunity

How do you tap the biggest cannabis opportunities to come? It’s simple: don’t do what everybody else is doing.

When cannabis stocks were shooting through the roof in 2018, companies were luring investors with optimistic forecasts for growth. But it wasn’t profit growth.

In reality, companies were simply promising to grow incredible amounts of weed, moving from zero production to 20,000 kilograms of annual capacity in as little as 15 months. Investors were smitten.

But we eventually learned that, like other crops, cannabis would be subject to pricing commoditization. Nearly every company has dealt with falling selling prices, which should only continue as industry supply ramps.

How to do you prevent pricing erosion in a commoditized market? One word: branding. Branding is the reason why Coca-Cola Co can sell you five cents worth of commodities for a dollar. No one else is selling what Coke offers, even if the base ingredients are available anywhere.

Cannabis companies have caught on, and are now attempting to create their own brands from scratch. What percentage of these upstart brands will succeed in having millions of consumers remain loyal to them? Likely not many.

The best way to create a brand that customers know and love is to leverage a brand that customers already know and love. That’s just what Hexo Corp. (TSX:HEXO)(NYSE:HEXO) is doing.

Hexo’s management team realized a long time ago that it couldn’t create billions in market value all on its own. Rather, it focused on building the industry’s first platform.

Hexo now has world-class research and development facilities, massive grow houses, and packaging and distribution capabilities. Any outside company with an existing brand can quickly and efficiently tap into Hexo’s infrastructure to spin-up cannabis products.

Here’s an example. Last year, Hexo worked with Molson Coors Canada Inc. to co-create cannabis drinks. The products should hit shelves this month. What’s more likely to succeed: a Molson-branded cannabis drink or a beverage from an unknown pot start-up? Hexo is betting on the former.

With a $475 million market cap, investors haven’t caught on to how powerful Hexo’s business model is. It’s already attracted Fortune 500 partners, and this year, it plans on closing several more.

It doesn’t matter where these companies are located or what industry they serve, Hexo can deliver on their cannabis needs without requiring them to invest millions of dollars into their own infrastructure.

Which pot stock would I rather own over the next 50 years? The one that can tap literally any cannabis opportunity that presents itself. That’s Hexo Corp.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Why Cannabis Stocks Popped Up to 80% on Tuesday

Despite short-term volatility, the long-term investment potential of pot stocks shines after the U.S. policy shift.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Rallied 80% in April

Canopy Growth (TSX:WEED) stock has seen shares surge by 80% on the back of the potential for reclassification in the…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Cannabis Stocks Surged on Tuesday

Cannabis stocks surged this week as the United States made yet another move towards legalization -- the biggest in over…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024? 

Aurora Cannabis (TSX:ACB) stock has been rising higher on the back of some broad cannabis market news, but will it…

Read more »

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »